Gilder Gagnon Howe & Co. LLC reduced its stake in shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN – Get Rating) by 44.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 144,476 shares of the company's stock after selling 114,021 shares during the quarter. Gilder Gagnon Howe & Co. LLC's holdings in Biohaven Pharmaceutical were worth $17,131,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of BHVN. Thrivent Financial for Lutherans purchased a new position in Biohaven Pharmaceutical during the fourth quarter valued at approximately $93,941,000. Viking Global Investors LP increased its position in shares of Biohaven Pharmaceutical by 177.0% in the first quarter. Viking Global Investors LP now owns 966,139 shares of the company's stock valued at $114,555,000 after buying an additional 617,356 shares in the last quarter. American Century Companies Inc. increased its position in shares of Biohaven Pharmaceutical by 259.4% in the first quarter. American Century Companies Inc. now owns 684,834 shares of the company's stock valued at $81,201,000 after buying an additional 494,275 shares in the last quarter. Eversept Partners LP increased its position in shares of Biohaven Pharmaceutical by 104.6% in the first quarter. Eversept Partners LP now owns 644,666 shares of the company's stock valued at $76,438,000 after buying an additional 329,537 shares in the last quarter. Finally, Eventide Asset Management LLC increased its position in shares of Biohaven Pharmaceutical by 23.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,635,000 shares of the company's stock valued at $225,319,000 after buying an additional 310,000 shares in the last quarter. 78.19% of the stock is currently owned by hedge funds and other institutional investors.
Get
Biohaven Pharmaceutical alerts:
Insider Activity
In other Biohaven Pharmaceutical news, Director Gregory Bailey purchased 38,000 shares of the firm's stock in a transaction dated Friday, August 19th. The shares were acquired at an average price of $148.04 per share, with a total value of $5,625,520.00. Following the purchase, the director now directly owns 2,583,658 shares in the company, valued at approximately $382,484,730.32. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 12.40% of the company's stock.
Analyst Ratings Changes
A number of analysts have recently commented on the company. Piper Sandler cut Biohaven Pharmaceutical from an "overweight" rating to a "neutral" rating and set a $149.00 price objective for the company. in a research report on Thursday, August 18th. Wedbush cut Biohaven Pharmaceutical from an "outperform" rating to a "neutral" rating and set a $148.50 price target for the company. in a research report on Monday, August 8th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $157.17.
Biohaven Pharmaceutical Stock Performance
NYSE BHVN opened at $150.99 on Tuesday. The stock's fifty day moving average is $147.39 and its two-hundred day moving average is $133.36. The firm has a market capitalization of $10.80 billion, a P/E ratio of -10.19 and a beta of 1.04. Biohaven Pharmaceutical Holding Company Ltd. has a fifty-two week low of $79.01 and a fifty-two week high of $151.51.
Biohaven Pharmaceutical (NYSE:BHVN – Get Rating) last released its quarterly earnings data on Friday, August 5th. The company reported ($6.21) earnings per share for the quarter, missing analysts' consensus estimates of ($2.79) by ($3.42). The business had revenue of $215.08 million during the quarter, compared to the consensus estimate of $209.33 million. As a group, sell-side analysts forecast that Biohaven Pharmaceutical Holding Company Ltd. will post -13.48 EPS for the current year.
Biohaven Pharmaceutical Profile
(Get Rating)
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.
Featured Articles
- Get a free copy of the StockNews.com research report on Biohaven Pharmaceutical (BHVN)
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN – Get Rating).
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
